Nexstim Plc (NXTMH:HEX, NXTMS:STO) (“Nexstim” or the “Company”), a medical technology company with a pioneering navigated non-invasive brain stimulation system, announces the resolutions adopted after voting at its Extraordinary General Meeting of shareholders held today on 20 February 2017.
Approving the unauthorised directed issuances of shares
The Extraordinary General Meeting of Shareholders approved the unauthorised directed issuances of 15,602,127 shares in Nexstim to Bracknor and Sitra.
Approving the unauthorised issuances of special rights entitling to shares
The Extraordinary General Meeting of Shareholders approved the unauthorised issuances to Bracknor and Sitra of special rights entitling to 31,167,761 shares in Nexstim. The Board of Directors will be authorised to amend the existing and registered terms and conditions of the issued special rights entitling to shares.
Authorising the Board of Directors to resolve on share issues, as well as option rights and other special rights entitling to shares
The Extraordinary General Meeting of Shareholders authorised the Board of Directors to resolve on share issues as well as issues of option rights and other special rights entitling to shares, pursuant to Chapter 10 of the Finnish Companies Act as follows:
The shares issued under the authorisation are new or those in Nexstim's possession. Under the authorisation, a maximum number of 29,412,792 shares can be issued. Shares, options and other special rights entitling to shares can be issued in one or more tranches.
Under the authorisation, the Board of Directors may resolve upon issuing new shares to Nexstim itself. However, Nexstim, together with its subsidiaries, may not at any time own more than 10 per cent of all its registered shares.
The Board of Directors is authorised to resolve on all terms for the share issue and granting of the special rights entitling to shares. The Board of Directors is authorised to resolve on a directed share issue and issue of the special rights entitling to shares in deviation from the shareholders’ pre-emptive right, provided that there is a weighty financial reason for the Nexstim to do so.
The authorisation would be effective for five (5) years from the date of the resolution of the Extraordinary General Meeting. This authorisation would not replace previous authorisations granted to the Board of Directors.
Minutes of the Extraordinary General Meeting
The minutes of the Extraordinary General Meeting will be published on, or by, 6 March 2017, on Nexstim's website.
Commenting on the approval, Chairman and CEO Martin Jamieson said: “I am pleased that the company now has the financial resources to complete its clinical programme and 510k de novo filing process for stroke rehabilitation. It is a very exciting time for Nexstim and over the next 18months we will be preparing for commercial launch of our therapy platform in the USA, China and Europe.”
Martin Jamieson, CEO
Martin Jamieson, Chairman and CEO
UB Securities Oy (Certified Adviser)
+358 (0)9 2538 0246
Citigate Dewe Rogerson
+44 (0)207 2821066
About Nexstim Plc
Nexstim is a medical technology company which has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system as the first and only FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (nTMS) system for pre-surgical mapping of the motor and speech cortices. Based on the same technology platform, the company has developed a system called Navigated Brain Therapy (NBT®) which is CE-marked for chronic neuropathic pain, major depression and stroke therapy. Nexstim's shares are listed on Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com.